Viral resistance in hepatitis B: Prevalence and management

Fred Poordad, Grace M. Chee

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Hepatitis B is a DNA virus affecting hundreds of millions of individuals worldwide. As the clinical sequelae of cirrhosis and hepatocellular cancer are increasingly recognized to be related to viral levels, the impetus increases to offer treatment to those previously not treated. With the development of more robust antivirals with reasonable safety profiles, long-term treatment is becoming more common. The oral nucleos(t)ide analogs have become the preferred first-line therapies for most genotypes of hepatitis B. Five are now available, all with different potencies and resistance profiles. Long-term data spanning several years are now available for most compounds in this arena. This article focuses on the common natural variants and those secondary to nucleos(t)ide therapy, as well as diagnostic methods to detect resistance.

Original languageEnglish (US)
Pages (from-to)62-69
Number of pages8
JournalCurrent Gastroenterology Reports
Issue number1
StatePublished - Feb 2010
Externally publishedYes


  • Genotypic mutation
  • Genotypic resistance
  • Hepatitis B
  • Nucleoside analog
  • Phenotypic resistance

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Viral resistance in hepatitis B: Prevalence and management'. Together they form a unique fingerprint.

Cite this